Financial Performance - For the six months ended September 30, 2025, total revenue decreased by approximately HK$24.0 million or 6.9% to approximately HK$322.8 million compared to HK$346.8 million for the same period in 2024[13][17]. - Gross profit for the same period decreased by approximately HK$16.7 million or 9.2% to approximately HK$165.3 million, with a gross profit margin of approximately 51.2%, down from 52.5%[14][18]. - The Group recorded a profit attributable to owners of the parent of approximately HK$2.8 million, a decrease from approximately HK$23.7 million in the same period of 2024, driven by weakened consumer sentiment[24]. - Profit before tax decreased significantly to HK$2,539,000, a decline of 89.9% from HK$25,152,000 in the previous year[134]. - Profit for the period was HK$2,799,000, compared to HK$23,742,000 in the same period last year, representing a decrease of 88.2%[135]. - Basic and diluted earnings per share attributable to ordinary equity holders of the parent was HK$0.25 cents, down from HK$2.10 cents in the previous year[136]. - Total comprehensive income for the period was HK$1,909,000, a significant drop from HK$24,004,000 in the same period of 2024[135]. Revenue Breakdown - The Group's sales declined by 4.4% during the period from April to September 2025 compared to the same period in 2024, influenced by changing consumer behavior among mainland Chinese tourists[30]. - The Group's revenue from western pharmaceutical and health food products decreased by 25.5% compared to the corresponding period in 2024, amid a moderate contraction in the respiratory health market[37]. - Revenue from contracts with customers for the six months ended September 30, 2025, was HK$321,460,000, down from HK$344,812,000 in 2024, reflecting a decline of 6.8%[164]. - The Chinese Pharmaceutical segment generated revenue of HK$292,825,000, a decrease of 4.4% from HK$306,351,000 in 2024[161]. - The Western Pharmaceutical segment reported revenue of HK$28,635,000, down 25.5% from HK$38,461,000 in the previous year[161]. Expenses and Costs - Selling and distribution expenses slightly decreased by approximately HK$0.2 million or 0.1% to approximately HK$131.7 million, attributed to cost-saving measures offset by increased marketing costs for e-commerce expansion[20]. - Administrative expenses decreased by approximately HK$9.4 million or 14.9% to approximately HK$54.0 million, mainly due to a reduction in legal and professional fees[21]. - Other expenses decreased significantly by approximately HK$1.2 million or 93.6% to approximately HK$0.1 million, primarily due to lower losses on disposal of investment properties[22]. - The Group recognized a cost of inventories as an expense of HK$144,593,000, slightly lower than HK$151,566,000 in 2024[182]. - Finance costs for the six months ended September 30, 2025, amounted to HK$8,849,000, a decrease from HK$14,954,000 in 2024, reflecting a reduction of approximately 40.8%[185]. Assets and Liabilities - As of September 30, 2025, the Group's total assets were approximately HK$1,689.6 million, a decrease from approximately HK$1,735.2 million as of March 31, 2025[44]. - The Group's total cash and cash equivalents were approximately HK$121.2 million as of September 30, 2025, compared to approximately HK$132.3 million as of March 31, 2025[45]. - Total current liabilities increased to HK$481,833,000 as of September 30, 2025, up from HK$358,933,000 on March 31, 2025, representing a 34.2% increase[138]. - Non-current liabilities decreased significantly to HK$26,303,000 from HK$196,746,000, a reduction of 86.6%[138]. - The total equity attributable to owners of the parent increased to HK$1,182,950,000 from HK$1,181,068,000, reflecting a growth of 0.2%[139]. Cash Flow - Cash generated from operations increased to HK$35,971,000 in the six months ended September 30, 2025, compared to HK$32,825,000 in the same period of 2024, reflecting a growth of approximately 6.5%[143]. - Net cash flows from operating activities for the six months ended September 30, 2025, were HK$36,184,000, up from HK$33,529,000 in 2024, indicating an increase of about 7.9%[143]. - The company reported net cash flows from investing activities of HK$31,033,000 for the six months ended September 30, 2025, a significant decrease from HK$267,485,000 in the previous year[144]. - New bank borrowings increased to HK$95,719,000 in the six months ended September 30, 2025, compared to HK$47,815,000 in the same period of 2024, representing a 100% increase[145]. - Cash and cash equivalents at the end of the period rose to HK$121,169,000, up from HK$96,276,000, reflecting a 26% increase[145]. Corporate Governance and Compliance - The Company has maintained compliance with the Corporate Governance Code throughout the review period, except for the deviation where the roles of chairman and managing director are held by the same individual[117]. - All Directors confirmed compliance with the Model Code for Securities Transactions throughout the review period, with no incidents of non-compliance noted[125]. - The Company emphasizes high standards of corporate governance to enhance competitiveness, operational efficiency, and shareholder value[115]. - The Audit Committee, comprising three independent non-executive Directors, has reviewed the unaudited condensed consolidated financial information for the six months ended September 30, 2025[126]. Shareholder Information - As of September 30, 2025, Mr. Tang Ching Ho held 810,322,940 shares, representing approximately 72.02% of the Company's total issued share capital[78]. - The Company has not granted any rights to acquire shares or debentures to any Director or chief executive during the review period[86]. - The share option scheme adopted on August 22, 2023, will remain in force for 10 years, with approximately 8 years remaining until August 2033[98]. - The 2023 Scheme allows for the refreshment of the Scheme Mandate Limit after 3 years from the adoption date, subject to shareholder approval[102].
位元堂(00897) - 2026 - 中期财报